牛牛AI助手已提取核心信息
George Simeon, associated with CRISPR Therapeutics AG [CRSP], engaged in a significant acquisition of the company's common stock on February 27, 2024. The transaction, which is currently in progress, involved the purchase of a total of 1,048,951 shares at a uniform price of $71.50 per share. Following these transactions, Simeon's holdings in CRISPR Therapeutics amount to 769,196 shares. The nature of the indirect beneficial ownership is detailed in notes associated with the transaction records.
George Simeon, associated with CRISPR Therapeutics AG [CRSP], engaged in a significant acquisition of the company's common stock on February 27, 2024. The transaction, which is currently in progress, involved the purchase of a total of 1,048,951 shares at a uniform price of $71.50 per share. Following these transactions, Simeon's holdings in CRISPR Therapeutics amount to 769,196 shares. The nature of the indirect beneficial ownership is detailed in notes associated with the transaction records.
与CRISPR Therapeutics AG [CRSP] 有关联的乔治·西蒙于2024年2月27日对该公司的普通股进行了重大收购。该交易目前正在进行中，涉及以每股71.50美元的统一价格购买总共1,048,951股股票。这些交易之后，西蒙在CRISPR Therapeutics中持有的股份为769,196股。间接受益所有权的性质详见与交易记录相关的附注。
与CRISPR Therapeutics AG [CRSP] 有关联的乔治·西蒙于2024年2月27日对该公司的普通股进行了重大收购。该交易目前正在进行中，涉及以每股71.50美元的统一价格购买总共1,048,951股股票。这些交易之后，西蒙在CRISPR Therapeutics中持有的股份为769,196股。间接受益所有权的性质详见与交易记录相关的附注。
有用
没用